The oral transmucosal drugs global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Oral Transmucosal Drugs Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size – The oral transmucosal drugs market size has grown strongly in recent years. It will grow from $36.34 billion in 2023 to $39.70 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to advancements in diagnostic capabilities, aging demographics, environmental pollutants, genetic susceptibilities, enhanced detection rates, faster relief facilitated by fast drug absorption, and better adherence.
The oral transmucosal drugs market size is expected to see strong growth in the next few years. It will grow to $56.83 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to advancements in personalized medicine, increasing research on novel drug delivery systems, expanding geriatric population, growing awareness of oral health, rising demand for non-invasive treatments, and evolving regulatory landscapes. Major trends in the forecast period include adoption of novel formulations, personalized medicine approaches, telehealth advancements, integration of digital health technologies and technological innovations in pharmaceuticals.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report
Scope Of Oral Transmucosal Drugs MarketThe Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Oral Transmucosal Drugs Market Overview
Market Drivers -The rising incidence of Parkinson’s disease is expected to propel the growth of the oral transmucosal drug market going forward. Parkinson’s disease refers to a progressive neurological condition causing tremors, stiffness, and movement difficulties due to a reduction in dopamine-producing cells in the brain. The rising prevalence of Parkinson’s disease is due to aging demographics, environmental pollutants, genetic susceptibilities, and advancements in diagnostic capabilities that enhance detection rates. Oral transmucosal drugs support Parkinson’s disease treatment by facilitating fast drug absorption and overcoming digestive challenges, leading to faster relief, better adherence, and possibly fewer motor complications. For instance, in December 2022, according to the Parkinson’s Foundation, a US-based non-profit organization, approximately 1 million individuals in the United States currently have Parkinson’s disease (PD), which is expected to increase to 1.2 million by 2030. Therefore, the rising incidence of Parkinson’s disease is driving the growth of the oral transmucosal drug market.
Market Trends – Major companies operating in the oral transmucosal drug market focus on developing innovative drug delivery solutions, such as sublingual vitamin spray, to enhance drug delivery efficacy, improve patient convenience, and optimize therapeutic outcomes. A sublingual vitamin spray is an oral transmucosal drug delivery system that provides vitamins directly into the bloodstream via the mucous membranes under the tongue. This method bypasses the gastrointestinal tract and liver metabolism, allowing for rapid and efficient absorption of the vitamins. For instance, in October 2022, Vestige Marketing, an India-based wellness and fitness company, introduced Absorvit, a sublingual vitamin spray that provides swift absorption and rapid results. This innovative product offers 3–10 times greater absorption than traditional oral methods. It contains upgraded forms and precise doses of essential vitamins, including B12, C, D, and multivitamins, ensuring optimal nutrition delivery. Absorvit represents a convenient and efficient way to supplement vital nutrients, enhancing overall wellness.
The oral transmucosal drugs market covered in this report is segmented –
1) By Product Type: Tablets, Films, Liquid And Spray, Other Product Types
2) By Indication: Opioid Dependence, Nausea And Vomiting, Erectile Dysfunction, Neurological Disorders, Other Indications
3) By Route Of Administration: Sublingual Mucosa, Buccal Mucosa, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Get an inside scoop of the oral transmucosal drugs market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15627&type=smp
Regional Insights – North America was the largest region in the oral transmucosal drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies – Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd, Wockhardt Ltd.
Table of Contents 1. Executive Summary2. Oral Transmucosal Drugs Market Report Structure3. Oral Transmucosal Drugs Market Trends And Strategies4. Oral Transmucosal Drugs Market – Macro Economic Scenario5. Oral Transmucosal Drugs Market Size And Growth…..27. Oral Transmucosal Drugs Market Competitor Landscape And Company Profiles28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
